Skip to main content
Fig. 3 | BMC Nephrology

Fig. 3

From: Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach

Fig. 3

Comparison of the clinical data between different anti-PLA2R titer groups before and after monthly mini-dose rituximab treatment. A. Decrease in urinary protein excretion; B. Increase in serum albumin; C. Changes in the estimated glomerular filtration rate; D. Overall remission rate. Blue line: low anti-PLA2R titer group, red line: high anti-PLA2R titer group. PLA2R: phospholipase A2 receptor. *p < 0.05, ** p < 0.01

Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us